(Press-News.org) What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never recover their health, even with antiretroviral treatment?
Dr. Madeleine Durand and Andrés Finzi, researchers at the CRCHUM, Université de Montréal’s affiliated hospital research centre, will explore this through the launch of a groundbreaking clinical trial this fall.
Two studies, one approach
With the publication of a remarkable study in 2023, the two scientists and Mehdi Benlarbi, a PhD student in Finzi’s lab, showed a keen interest in the HIV molecule gp120. The virus is known to infect CD4 cells responsible for activating the defences of the body’s immune system, but the researchers suspected it does more than that.
In fact, in one in three people, gp120 circulates in the blood, acting as a viral toxin—even when the HIV viral load is undetectable. It attaches itself to healthy cells, targeting them for elimination by the immune system, which ends up destroying its own defences, as shown by Finzi’s lab back in 2016.
In a new study, published in August 2025 in eBioMedicine, the CRCHUM scientific team shows that certain non-neutralizing antibodies, known as anti-cluster A antibodies, exacerbate this situation by attacking these uninfected CD4 cells made vulnerable by the action of gp120.
“This form of immune sabotage leads to a decrease in the number of CD4 cells and has a direct impact on the ability of the immune system of PLWH to fight the virus,” explained Finzi, a professor of virology in UdeM’s Faculty of Medicine.
“Conversely, in our study, we show that other rarer antibodies—anti-CD4 Binding Site (CD4BS) antibodies—block gp120 from binding to the surface of healthy CD4 cells and protect them,” he added.
This discovery was made possible with blood samples from the Canadian HIV and Aging Cohort Study (CHACS) led by Dr. Madeleine Durand. This cohort included 850 PLWH and 250 control subjects.
“Only 15 percent of PLWH have these ‘good’ antibodies in their plasma, in addition to the ‘bad’ antibodies that get rid of healthy cells,” said Durand, clinical professor at the Faculty of Medicine at Université de Montréal.
Fostemsavir: more than just an antiviral?
In a third study, published in The Journal of Infectious Diseases, the CRCHUM scientific trio, aided by Jonathan Richard, a research associate in Finzi's laboratory, shows that people treated with fostemsavir have lower levels of “bad” antibodies.
The research group had already demonstrated in a previous study that fostemsavir, a drug approved by Health Canada for PLWH in cases of treatment failure, blocked the toxic effect of gp120.
“This drug, produced and supplied by our partner ViiV Healthcare, deforms the viral protein in an unprecedented way,” said Finzi. “There are less of the “bad” antibodies to label uninfected CD4 cells, as the drug renders gp120 incapable of sticking to these cells. It neutralizes its toxicity.”
This mechanism, observed in samples from Italian and ViiV Healthcare biobanks, suggests that fostemsavir could improve immunity even in people with a well-controlled virus.
“It would restore CD4 cells to their role as the orchestra conductor of the immune system, and enable PLWH to enjoy better health,” said Durand.
A two-year trial on 150 people
These scientific advances have led to the RESTART trial, a randomized controlled trial to be launched this fall at the CHUM, piloted by Durand. 150 people will be recruited and followed over a two-year period.
The goal is to test whether fostemsavir, combined with an existing antiretroviral therapy, can have beneficial effects on the cardiovascular health of people living with HIV.
In PLWH, the sustained activation of the immune system leads to chronic inflammation that can cause health problems such as cardiovascular diseases, osteoporosis or neurocognitive decline.
These problems, which clinicians call early-onset comorbidities, arise around 15 years earlier than in the general population.
“Our clinical trial is based on a personalized medicine approach”, said Durand. Only PLWH with a detectable level of gp120 in their blood will be able to take part in the trial. A test developed by Finzi’s team can detect this viral protein in the plasma of participants.
“Participants will undergo two cardiac CT scans, at the beginning and the end of the study, to measure coronary plaque progression,” she said.
A marker of cardiovascular disease, this measurement is made through imaging and will be carried out by CRCHUM scientist Dr. Carl Chartrand-Lefebvre, director of UdeM’s Department of Radiology, Radiation Oncology and Nuclear Medicine.
A different approach to treatment
Funded by the Canadian Institutes for Health Research, the RESTART trial offers a new way of thinking about HIV treatment. It is part of an effort to better understand the aging of people living with HIV and to improve their quality of life.
“Suppressing HIV viral load in plasma with antiretrovirals, the current standard of treatment, may not be enough,” said Durand. “If our clinical trial confirms that soluble gp120 is a legitimate therapeutic target, we will then have several additional ways to attack the virus, whether with a drug or broadly neutralizing antibodies targeting the CD4BS.”
According to the World Health Organization, almost 41 million people were living with HIV in 2024 and 1.3 million people acquired HIV.
Author: Bruno Geoffroy
###
About the CHUM Research Centre (CRCHUM)
Université de Montréal's affiliated hospital research centre, the CRCHUM, is one of North America’s leading hospital research centres. It strives to improve the health of adults through a continuum of research spanning disciplines such as basic science, clinical research and population health. About 2,170 people work at CRCHUM. These include more than 570 researchers and more than 540 graduate students and postdoctoral fellows. crchum.com
About Université de Montréal
Deeply rooted in Montréal and dedicated to its international mission, Université de Montréal is one of the top universities in the French-speaking world. Founded in 1878, Université de Montréal today has 13 faculties and schools, and together with its two affiliated schools, HEC Montréal and Polytechnique Montréal, constitutes the largest centre of higher education and research in Québec and one of the major centres in North America. It brings together 2,300 professors and researchers and has close to 67,000 students. umontreal.ca
END
The RESTART trial: a drug to block a toxic HIV molecule
Combined with regular antiretroviral therapy, could fostemsavir have beneficial effects on the cardiovascular health of people living with HIV? CRCHUM researchers investigate
2025-10-02
ELSE PRESS RELEASES FROM THIS DATE:
New polymer designs for beyond-5G telecommunications
2025-10-02
With the rollout of fifth-generation (5G) telecommunications networks and 6G looming on the horizon, the demand for advanced materials that can handle high-frequency signals is rising rapidly. These systems use electromagnetic waves ranging from tens to hundreds of gigahertz (GHz), where signals are highly sensitive to transmission loss, interference, and distortion. To address these issues, scientists and engineers rely on special insulating materials, known as dielectrics, which help guide signals with minimal loss.
Polymer-based dielectrics are particularly attractive. ...
Hanbat National University study finds quantum computing can make homes smarter and greener
2025-10-02
Residential heating, ventilation, and air conditioning (HVAC) systems constitute a significant proportion of energy usage in buildings, necessitating energy management optimization. In this context, occupancy aware HVAC control is a promising option with 20-50% energy savings in homes. However, occupancy sensing technology suffers from long payback times, privacy issues, and poor comfort. Moreover, there is an increasing need for further advanced technologies that help regulate indoor air quality in addition to energy control.
To meet these expectations, scientists have recently turned to intelligent control methods such as ...
Tiny cell messengers in obese individuals accelerate Alzheimer’s-linked plaque buildup in the brain
2025-10-02
HOUSTON – Oct. 2, 2025 – Obesity has long been acknowledged as a risk factor for a wide range of diseases, but a more precise link between obesity and Alzheimer’s disease has remained a mystery – until now.
A first-of-its-kind study from Houston Methodist found that adipose-derived extracellular vesicles, tiny cell-to-cell messengers in the body, can signal the buildup of amyloid-β plaque in obese individuals. These plaques are a key feature of Alzheimer’s disease.
The study, “Decoding Adipose–Brain Crosstalk: Distinct Lipid Cargo in Human Adipose-Derived ...
Do elephants know when we're looking at them?
2025-10-02
Kyoto, Japan -- With their massive flapping ears and long trunks, it isn't hard to believe that elephants tend to rely on acoustic and olfactory cues for communication. They use gestures and visual displays to communicate as well, but we don't really know how much. Visual communication research has mainly focused on species that are primarily visual, like nonhuman primates.
A previous study demonstrated that African savanna elephants can recognize human visual attention based on a person's face and body orientation, but this had yet to be investigated in their Asian cousins. Asian elephants split from African elephants millions of years ago, so their behavior and cognition differ ...
Psilocybin targets brain circuits to relieve chronic pain, depression
2025-10-02
PHILADELPHIA— Researchers at Penn Medicine have identified specific brain circuits that are impacted by psilocybin—the active compound found in some psychedelic mushrooms—which could lead to new paths forward for pain and mental health management options. Chronic pain affects more than 1.5 billion people worldwide and is often deeply entangled with depression and anxiety, creating a vicious cycle that amplifies suffering and impairs quality of life. The study from the Perelman School of Medicine at the University of Pennsylvania- ...
MPs and public overestimate time left for climate action, study finds
2025-10-02
A new study has found that UK Members of Parliament (MPs) and the public overestimated the time left to meet a critical deadline for limiting global warming.
Researchers at the University of East Anglia (UEA) surveyed a representative sample of the previous House of Commons, and the public in Britain, Canada, Chile and Germany, on their knowledge of a well-publicised statement from the UN’s Intergovernmental Panel on Climate Change (IPCC).
It related to when global ...
Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO)
2025-10-02
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) to be published in the journal Nature Medicine. “Even though there are several options on the market, the reality is that semaglutide and tirzepatide are so effective that they should be the first choice in almost all cases,” says co-first author Dr Andreea Ciudin.
The authors are an international team of obesity experts led by the co-chairs of the EASO Obesity Management Working Group who are Dr ...
Generative AI is more efficient than nature at designing proteins to edit the genome
2025-10-02
Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed and experimentally validated new synthetic proteins that can edit the human genome more efficiently than proteins provided by nature. This work, a global pioneer published today in the journal Nature Biotechnology, will be of great use in improving the current gene editing tools used in biotechnology research and personalized medicine by developing cellular (CAR-T) and gene therapies, especially to treat ...
ESMT Berlin study: ESG ratings show limited financial impact in the Gulf
2025-10-02
Firms in the Gulf region are increasingly expected to align with environmental, social, and governance (ESG) standards. Yet the link between ESG performance and financial outcomes remains ambiguous. A new study examines whether publicly listed companies in GCC member states that achieve high ESG ratings also deliver superior financial performance.
The study “ESG and financial performance in the Gulf Cooperation Council” was authored by Catalina Stefanescu-Cuntze, professor of management science and faculty lead of the Master in Analytics and Artificial Intelligence Program at ESMT Berlin, together with Rodrigo Tavares and Catarina Sá from Nova School ...
Scalable AI tracks motion from single molecules to wildebeests
2025-10-02
University of Michigan researchers have developed a tool powered by artificial intelligence that can help them examine the behavior of a single molecule out of a sea of information in the blink of an eye—or at least overnight.
Understanding the behavior of single molecules is important: it can lead to knowledge of different cellular processes or track how diseases begin and progress. To track the behavior of single molecules, researchers tag the molecules with what's called a fluorophore. They excite these fluorophores with a laser, then use powerful microscopes to follow the behavior of the tagged molecules over time.
But ...
LAST 30 PRESS RELEASES:
In global collaboration, IU scientists unlock secrets to the building blocks of the universe
Young adults fear mass shootings but don’t necessarily support gun control
How unlocking ‘sticky’ chemistry may lead to better, cleaner fuels
Cutting balloon treatment prior to stent placement comparable to intravascular lithotripsy for patients with calcified coronary artery disease
Novel sirolimus-eluting balloon appears noninferior to conventional therapies for treatment of in-stent restenosis
Nearly half of US workers don’t know work experience could count toward a degree, according to University of Phoenix survey
Super-high-pressure non-compliant balloons for treatment of calcified coronary lesions noninferior to intravascular lithotripsy
Saudi Native Dr. Hani K. Najm named next vice president of the American College of Cardiology
Getting steps in one long walk a day cuts risk of death and CVD better than multiple short walks
The way you walk: 10–15 minute bouts of walking better for your cardiovascular health than shorter strolls
Beyond electronics: harnessing light for faster computing
Researchers find possible cause for increasing polarization
From soft to solid: How a coral stiffens its skeleton on demand
New software tool MARTi fast-tracks identification and response to microbial threats
Rare brain cell may hold the key to preventing schizophrenia symptoms
A new tool to find hidden ‘zombie cells’
New Cleveland Clinic research finds up to 5% of Americans carry genetic mutations associated with cancer risk
Once tadpoles lose lungs, they never get them back
Small group of users drive invasive species awareness on social media
One bad safety review can tank an Airbnb booking — Even among thousands of positive ones, new study finds
Text-based system speeds up hospital discharges to long-term care
California schools are losing tree canopy
How people learn computer programming
Exploring a mechanism of psychedelics
Scientists can now explore mechanisms behind attachment issues
Researchers watched students’ brains as they learned to program
An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program
AI-powered diabetes prevention program shows similar benefits to those led by people
New study may transform diagnosis of Britain’s number one cancer
Stillbirths in the United States
[Press-News.org] The RESTART trial: a drug to block a toxic HIV moleculeCombined with regular antiretroviral therapy, could fostemsavir have beneficial effects on the cardiovascular health of people living with HIV? CRCHUM researchers investigate